EUCTR2014-002384-15-AT进行中（未招募）1 期
Intravitreal Aflibercept treatment in RAP-Lesions, PED, hemorrhagic CNV and PCV - Aflibercept treatment for RAP, PED, hemorrhagic CNV and PCV
niversitätsklinik für Augenheilkunde und Optometrie0 个研究点目标入组 50 人开始时间: 2014年9月19日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Treatment naïve eyes with following subtypes of exsudative maculopathies will be included:
- •Retinal angiomatous proliferation lesions (RAP)
- •Pigment epithelium detachment (PED)
- •Hemorrhagic CNV (if the size of hemorrhage is either >50% of the lesion area or >1 disk area in size) )
- •Polypoidal choroidal vasculopathy (PCV)
- •Patients who have a BCVA score better than 20/400 in the study eye using ETDRS
- •Willingness and able to comply with clinic visits and study-related procedures
- •Proved a signed informed consent form
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Any prior treatment for exsudative maculopathy including photodynamic therapy and intravitreal anti-VEGF application in the study eye
- •Any surgical treatment of the eye within 3 months prior to baseline in the study eye
- •History of glaucoma filtration surgery, corneal transplant surgery or extracapsular extraction of cataract with phacoemulsification within six months preceding Visit 1, or a history of post-operative complications within the last 12 months preceding Visit 1 in the study eye (uveitis, cyclitis etc.)
- •History of uncontrolled glaucoma in the study eye (defined as intraocular pressure = 25 mmHg despite treatment with anti-glaucoma mediation)
- •Aphakia or absence of the posterior capsule in the study eye
- •Presence of a retinal pigment epithelial tear involving the macula in the study eye.
- •Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator, could either require medical or surgical intervention during the twelve-month study period to prevent or treat visual loss that might result from that condition
- •Active intraocular inflammation (grade trace or above) in the study eye.
- •Active or suspected ocular or periocular infection in the study eye.
- •Any active infection involving eyeball adnexa
- •Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye
- •Current iris neovascularization, vitreous hemorrhage, or tractional retinal detachment
- •in the study eye
- •Evidence of infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye
- •Other ocular conditions that require chronic concomitant therapy with systemic or topical ocular corticosteroids. Chronic concomitant therapy is defined as multiple doses taken daily for three or more consecutive days at any time within six months prior to screening or during the course of the study.
- •Pregnant or breast-feeding women.
- •Women of childbearing potential with either a positive pregnancy test result or no
- •pregnancy test at baseline are excluded. Postmenopausal women must be amenorrheic
- •for at least 12 months in order not to be considered of child bearing potential.
- •Sexually active men or women of childbearing potential who are unwilling to practice
- •adequate contraception during the study are excluded. (adequate contraceptive
- •measures include stable use of oral contraceptives or other prescription
- •pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening;
- •intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus
- •contraceptive sponge, foam, or jelly or diaphragm plus contraceptive sponge, foam, or
- •Allergy to fluorescein
- •Hypersensitivity to the active substance aflibercept or to any of the excipients (Polysorbate 20, Sodium dihydrogen phosphate, monohydrate, Disodium hydrogen phosphate, heptahydrate, Sodium chloride, Sucrose)
研究者
相似试验
已完成
3 期
The efficacy of intravitreal aflibercept given in a ‘treat and extend’ regime in the treatment of cystoid macular oedema secondary to central retinal vein occlusion.central retinal vein occlusion (CRVO).cystoid macular oedemaEye - Diseases / disorders of the eyeACTRN12615000417583Centre for Eye Research Australia20
已完成
不适用
Combination therapy of intravitreal aflibercept and topical bromfenac for RVOretinal vein occlusionJPRN-UMIN000022988Juntendo Urayasu Hospital40
已完成
4 期
The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO)Branch retinal vein occlusionJPRN-UMIN000023200Department of Ophthalmology, Akita University50
尚未招募
3 期
To investigate the role of Intravitreal Aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment.ACTRN12613001020774Greenlane Clinical Centre Auckland District Health Board50
已完成
不适用
Outcomes of intravitreal aflibercept (Eylea) treatment for treatment-naive contralateral eyes with neovascular age-related macular degeneration in patients whose treatment failed intravitreal ranibizumab in the first eyeeovascular age-related macular degenerationJPRN-UMIN000033786Seoul National University Hospital21